Lecanemab (formerly BAN2401) will now be filed for approval in the US, Europe, and Japan in the first quarter of next year via the regular review pathway. Biogen and Eisai used the accelerated ...

safety and biomarker results from the Phase 3 confirmatory Clarity AD clinical trial for lecanemab [1] (development code: BAN2401), at the 15 th Clinical Trials on Alzheimer's Disease (CTAD ...

Lecanemab, the first medication designed to remove amyloid beta, a protein believed to cause Alzheimer’s, was developed by Japan’s Eisai Co. and its U.S. partner, Biogen Inc. “We believe ...